RESUMEN
WHICH ARE SOMATIC DISEASES OF MIGRANT CHILDREN? Migrant children form a vulnerable and heterogeneous population estimated at 70 000 in France. Their health is influenced by their living conditions in their home country, stress and exposure to pathogens, unsanitary housing and food insecurity during their migratory route and in their host country, as well as their parents psychological disorders. They present malnutrition, nutritional de¬ficiencies (iron and vitamin D), various dental, skin and intestinal infections, a significant prevalence of tuberculosis, and sometimes imported parasitic infections (malaria, schistosomiasis ) and lead poisoning. An high prevalence of early neurodevelopmental pro¬blems is noticed. Their immunity is insufficient and catch-up vacci¬nation is most often necessary. They require the support of a socio-psycho-medico-educational care network.
QUELLES PATHOLOGIES SOMATIQUES AFFECTENT LES ENFANTS MIGRANTS ? Les enfants migrants forment une population vulnérable et hétérogène estimée à 70 000 personnes en France. Leur état de santé est influencé par les conditions de vie dans leur pays d'origine, l'exposition aux stress et aux agents pathogènes, à l'insalubrité de leur hébergement et à l'insécurité alimentaire durant leur parcours migratoire et dans leur pays d'accueil, ainsi que par les troubles psychologiques parentaux. Ils présentent des malnutritions, des carences nutritionnelles (martiale et en vitamine D), des infections dentaires, cutanées et digestives, avec une prévalence significative de tuberculose, parfois des parasitoses importées (paludisme, bilharziose ) et du saturnisme. On observe une prévalence importante des troubles précoces du neurodéveloppement. Leur immunité vaccinale est insuffisante, et un rattrapage est le plus souvent nécessaire. Ils requièrent une prise en charge dans un réseau de soins socio-psycho-médico-éducatif.
Asunto(s)
Trastornos Mentales , Migrantes , Niño , Humanos , Prevalencia , Trastornos Mentales/epidemiología , Padres , Francia/epidemiologíaRESUMEN
[This corrects the article DOI: 10.1016/j.lanepe.2022.100393.].
RESUMEN
Background: Multisystem inflammatory syndrome in children (MIS-C) is the most severe clinical entity associated with pediatric SARS-CoV-2 infection with a putative role of the spike protein into the immune system activation. Whether COVID-19 mRNA vaccine can induce this complication in children is unknown. We aimed to assess the risk of hyper-inflammatory syndrome following COVID-19 mRNA vaccine in children. Methods: We conducted a post-authorization national population-based surveillance using the French enhanced pharmacovigilance surveillance system for COVID-19 vaccines. All cases of suspected hyper-inflammatory syndrome following COVID-19 mRNA vaccine in 12-17-year-old children between June 15th, 2021 and January 1st, 2022, were reported. Cases were reviewed according to WHO criteria for MIS-C. The reporting rate of this syndrome was compared to the MIS-C rate per 1,000,000 12-17-year-old children infected by SARS-CoV-2. Findings: Up to January 2022, 8,113,058 COVID-19 mRNA vaccine doses were administered to 4,079,234 12-17-year-old children. Among them, 12 presented a hyper-inflammatory syndrome with multisystemic involvement. Main clinical features included male predominance (10/12, 83%), cardiac involvement (10/12, 83%), digestive symptoms (10/12, 83%), coagulopathy (7/12, 58%), cytolytic hepatitis (6/12, 50%), and shock (5/12, 42%). 4/12 (33%) required intensive care unit transfer, and 3/12 (25%) hemodynamic support. All cases recovered. In eight cases, no evidence of previous SARS-CoV-2 infection was found. The reporting rate was 1.5 (95%CI [0.8; 2.6]) per 1,000,000 doses injected, i.e. 2.9 (95%CI [1.5; 5.1]) per 1,000,000 12-17-year-old vaccinated children. As a comparison, 113 MIS-C (95%CI [95; 135]) occurred per 1,000,000 12-17-year-old children infected by SARS-CoV-2. Interpretation: Very few cases of hyper-inflammatory syndrome with multi-organ involvement occurred following COVID-19 mRNA vaccine in 12-17-year-old children. The low reporting rate of this syndrome, compared to the rate of post-SARS-CoV-2 MIS-C in the same age-group, largely supports the vaccination in a context of an important circulation of SARS-CoV-2. Funding: ESPID Fellowship Award; Grandir-Fonds de Solidarité Pour L'enfance.
RESUMEN
BACKGROUND: HIV is usually associated with weight loss. World health Organization (WHO) recommends early antiretroviral (ART) initiation, but data on the progression of body mass index (BMI) in participants initiating early ART in Africa are scarce. METHODS: The Temprano randomized trial was conducted in Abidjan to assess the effectiveness of early ART and Isoniazid (INH) prophylaxis for tuberculosis in HIV-infected persons with high CD4 counts below 800 cells/mm(3) without any indication for starting ART. Patients initiating early ART before December 2010 were included in this sub-study. BMI was categorized as: underweight (<18.5 kg/m(2)), normal weight (18.5-24.9 kg/m(2)), overweight (25-29.9 kg/m(2)) and obese (≥30 kg/m(2)). At baseline and after 24 months of ART, prevalence of being overweight or obese and factors associated with being overweight or obese were estimated using univariate and multivariate logistic regression. RESULTS: At baseline, 755 participants (78 % women; median CD4 count 442/mm(3), median baseline BMI 22 kg/m(2)) initiated ART. Among them, 19.7 % were overweight, and 7.2 % were obese at baseline. Factors associated with being overweight or obese were: female sex aOR 2.3 (95 % CI 1.4-3.7), age, aOR for 5 years 1.01 (95 % CI 1.0-1.2), high living conditions aOR 2.6 (95 % CI 1.5-4.4), High blood pressure aOR 4.3 (95 % CI 2.0-9.2), WHO stage 2vs1 aOR 0.7 (95 % CI 0.4-1.0) and Hemoglobin ≥95 g/dl aOR 3.0 (95 % CI 1.6-5.8). Among the 597 patients who attended the M24 visit, being overweight or obese increased from 20.4 to 24.8 % (p = 0.01) and 7.2 to 9.2 % (p = 0.03) respectively and factor associated with being overweight or obese was immunological response measured as an increase of CD4 cell count between M0-M24 (for +50 cells/mm(3): aOR 1.01; 95 % CI 1.05-1.13, p = 0.01). CONCLUSION: The weight categories overweight and obese are highly prevalent in HIV-infected persons with high CD4 cell counts at baseline, and increased over 24 months on ART in this Sub-Saharan African population.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/complicaciones , Obesidad/complicaciones , Sobrepeso/complicaciones , Adulto , Antituberculosos/uso terapéutico , Índice de Masa Corporal , Côte d'Ivoire/epidemiología , Femenino , Infecciones por VIH/tratamiento farmacológico , Humanos , Isoniazida/uso terapéutico , Masculino , Obesidad/epidemiología , Sobrepeso/epidemiología , Tuberculosis Pulmonar/prevención & control , Pérdida de Peso/efectos de los fármacosRESUMEN
OBJECTIVE: To assess the performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) test for active tuberculosis (TB) in HIV adults, and its variation over time in patients on antiretroviral therapy (ART) and/or isoniazide preventive therapy (IPT). METHODS: Transversal study and cohort nested in the Temprano ANRS 12136 randomized controlled trial assessing benefits of initiating ART earlier than currently recommended by World Health Organization, with or without a 6-month IPT. Performance of QFT-GIT for detecting active TB at baseline in the first 50% participants, and 12-month incidence of conversion/reversion in the first 25% participants were assessed. QFT-GIT threshold for positivity was 0.35 IU/ml. RESULTS: Among the 975 first participants (median baseline CD4 count 383/mm3, positive QFT-GIT test 35%), 2.7% had active TB at baseline. QFT-GIT sensitivity, specificity, positive and negative predictive value for active TB were 88.0%, 66.6%, 6.5% and 99.5%. For the 444 patients with a second test at 12 months, rates for conversion and reversion were 9.3% and 14%. Reversion was more frequent in patients without ART and younger patients. IPT and early ART were not associated with reversion/conversion. CONCLUSION: A negative QFT-GIT could rule out active TB in HIV-infected adults not severely immunosuppressed, thus avoiding repeated TB testing and accelerating diagnosis and care for other diseases. TRIAL REGISTRATION: ClinicalTrials.gov NCT00495651.
Asunto(s)
Recuento de Linfocito CD4 , Ensayo de Inmunoadsorción Enzimática , Infecciones por VIH/complicaciones , Infecciones por VIH/inmunología , Interferón gamma/análisis , Tuberculosis/complicaciones , Tuberculosis/diagnóstico , Adulto , Fármacos Anti-VIH/farmacología , Fármacos Anti-VIH/uso terapéutico , Côte d'Ivoire , Femenino , Estudios de Seguimiento , Infecciones por VIH/tratamiento farmacológico , Humanos , Isoniazida/farmacología , Masculino , Tuberculosis/prevención & controlRESUMEN
To evaluate the implication of WHO guidelines for serodiscordant couples, we interviewed HIV-infected adults on their partner's serostatus. We found that 12% with more than 500 CD4+ cells/µl should be recommended antiretroviral treatment (ART) because their partner was seronegative; 24% could be recommended not to start ART because their partner was seropositive; and 64% could not be given any recommendation regarding ART early initiation because they had either no stable partnership (30%) or were in a stable partnership with a partner whose status they were not aware of (34%).